-PTI With a view to strengthen Safety of passengers and check crimes against women in trains and stations, Railways will soon launch a 24x7 helpline which will be tracked on real-time basis across the country. The proposed pan India toll-free helpline, first-of-its- kind in Railways, is going to be launched shortly to provide round-the-clock security-related assistance to passengers, a senior Railway Ministry official involved with the project said. Passengers can use the helpline...

-Outlook India has long been the sleeping giant of global agriculture. But its misguided policies while boosting short-term output, yet may transform India into a food importer After decades on the sidelines of international agricultural trade, India was poised last year to become a major food supplier, overtaking traditional exporters of food grain and meat. This could prove to be flash in the pan. The sudden rise and fall of India...

-Bloomberg The corpse of Indian farmer Bengali Singh burned to ash atop a blazing funeral pyre on the banks of the river Ganges in 2006. Five years later, the dead man was recorded as being paid by India's $33 billion rural jobs program to dig an irrigation canal in Jharkhand state. Officials in his village and the surrounding region used at least 500 identities, including those of Singh, a disabled child of...

-The Times of India PATNA: The Bihar government, which keeps crying for more central assistance, could not spend Rs 1472.61 crore in 2012 and surrendered 100 per cent funds in 192 schemes, depriving the beneficiaries of the benefits, according to the CAG report for 2011-12 presented in state assembly on Tuesday. Central funds for several schemes also remained unutilized, it said. The CAG also regretted the lack of objective planning in utilization...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...